NHLBI plans to fund single-site clinical trials (R61/R33) testing therapeutic, behavioral, or prevention strategies, encouraging innovative designs.
Funder: National Institutes of Health
Due Dates: February 1, 2027 (New) | March 1, 2027 (Resubmission/Revision) | June 2, 2027 (New) | July 2, 2027 (Resubmission/Revision) | October 1, 2027 (New) | November 1, 2027 (Resubmission/Revision) | February 1, 2028 (New) | March 1, 2028 (Resubmission/Revision) | June 1, 2028 (New) | June 30, 2028 (Resubmission/Revision) | October 2, 2028 (New) | November 2, 2028 (Resubmission/Revision, final)
Funding Amounts: No budget cap; budgets must reflect actual project needs; up to 5 years total
Summary: Supports development and execution of investigator-initiated, single-site Phase II or later clinical trials relevant to NHLBI’s mission.
Key Information: Foreign applicants are eligible, but applications involving foreign subawards or subcontracts will not be considered.
The National Heart, Lung, and Blood Institute (NHLBI) supports investigator-initiated single-site clinical trials through a milestone-driven R61/R33 award. Eligible research includes efficacy, comparative effectiveness, pragmatic, and dissemination and implementation trials testing therapeutic, behavioral, or prevention strategies. Platform, adaptive, and Bayesian designs are encouraged. Research must address NHLBI priorities in heart, lung, blood, or sleep health and meet the NIH definition of a clinical trial.
The award combines a start-up phase with a full enrollment and trial execution phase. Applications must present a scientific rationale and comprehensive operational plan covering project management, recruitment and retention, performance milestones, trial conduct, and dissemination. NHLBI emphasizes community engagement from intervention design through implementation and sustainability, closing gaps in health outcomes within the U.S. population, and improving health for all.